ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 112 filers reported holding ACLARIS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.89 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $524,778 | +65.7% | 76,610 | +150.8% | 0.00% | – |
| Q2 2023 | $316,762 | +6.0% | 30,546 | -17.3% | 0.00% | – |
| Q1 2023 | $298,853 | +111.0% | 36,941 | +310.7% | 0.00% | – |
| Q4 2022 | $141,656 | -100.0% | 8,994 | -57.3% | 0.00% | -100.0% |
| Q3 2022 | $331,705,000 | +77.9% | 21,074 | +57.8% | 0.00% | – |
| Q2 2022 | $186,464,000 | +144.4% | 13,357 | +201.8% | 0.00% | – |
| Q1 2022 | $76,304,000 | -51.6% | 4,426 | -59.2% | 0.00% | – |
| Q4 2021 | $157,788,000 | -2.9% | 10,852 | +20.2% | 0.00% | – |
| Q3 2021 | $162,522,000 | +458.9% | 9,029 | +445.2% | 0.00% | – |
| Q2 2021 | $29,079,000 | +68.5% | 1,656 | -84.5% | 0.00% | – |
| Q2 2020 | $17,261,000 | +56.1% | 10,655 | +0.2% | 0.00% | – |
| Q1 2020 | $11,056,000 | -24.3% | 10,631 | +37.6% | 0.00% | – |
| Q4 2019 | $14,600,000 | +144.9% | 7,725 | +40.0% | 0.00% | – |
| Q3 2019 | $5,961,000 | -31.9% | 5,519 | +38.2% | 0.00% | – |
| Q2 2019 | $8,747,000 | -80.3% | 3,994 | -46.1% | 0.00% | – |
| Q1 2019 | $44,368,000 | +66120.9% | 7,407 | +82200.0% | 0.00% | – |
| Q4 2018 | $67,000 | -99.5% | 9 | -98.9% | 0.00% | – |
| Q3 2018 | $12,298,000 | -27.3% | 847 | 0.0% | 0.00% | – |
| Q2 2018 | $16,915,000 | -80.5% | 847 | -82.9% | 0.00% | – |
| Q1 2018 | $86,584,000 | -28.2% | 4,942 | +1.0% | 0.00% | – |
| Q4 2017 | $120,661,000 | +135.2% | 4,893 | +146.1% | 0.00% | – |
| Q3 2017 | $51,310,000 | -8.2% | 1,988 | -3.6% | 0.00% | – |
| Q2 2017 | $55,921,000 | +7396.1% | 2,062 | +8148.0% | 0.00% | – |
| Q1 2017 | $746,000 | -96.0% | 25 | -96.3% | 0.00% | – |
| Q4 2016 | $18,455,000 | +3.4% | 680 | -2.4% | 0.00% | – |
| Q3 2016 | $17,850,000 | +178.5% | 697 | +100.9% | 0.00% | – |
| Q2 2016 | $6,409,000 | -77.1% | 347 | -66.6% | 0.00% | – |
| Q4 2015 | $27,964,000 | – | 1,038 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |